Showing 2411-2420 of 3201 results for "".
- CPP Launches Network of Physician-led Medical Aesthetics Clinics Across UShttps://practicaldermatology.com/news/cpp-launches-network-of-physician-led-medical-aesthetics-clinics-across-us/2461442/Cosmetic Physician Partners Inc. ("CPP") is pleased to announce its official launch in the US with the closing of its 10th medical aesthetics clinic. Led by Dr. A. Jay Burns, Dr. Joel L. Cohen, Matt and Kathy Taranto and Dan Schacter, CPP is a partnership designed to provide physician o
- Anaslysis: CHL-Fe-based PDT Shows Activity Against Drug-Resistant C. acneshttps://practicaldermatology.com/news/chl-febased-photodynamic-therapy-shows-potent-activity-against-drug-resistant-c-acnes/2485327/Photodynamic therapy (PDT) using sodium iron chlorophyllin (CHL-Fe) and red light achieved consistent bactericidal effects against drug-resistant Cutibacterium acnes (C. acnes) strains in vitro, according to new study finding
- Seborrheic Dermatitis Linked to Systemic Epithelial Barrier Diseases: Analysishttps://practicaldermatology.com/news/seborrheic-dermatitis-linked-to-systemic-epithelial-barrier-diseases-analysis/2484390/Findings from a new retrospective cohort suggest individuals living with seborrheic dermatitis are more likely to have other epithelial barrier diseases such as rosacea, alopecia areata, and celiac disease. Investigators publish
- Neutrogena Recalls Makeup Wipes Due to Bacterial Contaminationhttps://practicaldermatology.com/news/neutrogena-recalls-makeup-wipes-due-to-bacterial-contamination/2484214/The Food and Drug Administration (FDA) issued a Class II risk level for a line of Neutrogena's makeup-removing facial wipes due to potential bacterial infection, according to a statement from the agency. In a brief message, the FDA reported that an internal investigation by the manufacture
- Long-Term Baricitinib Data Reinforce Potential in Adolescents With AAhttps://practicaldermatology.com/news/long-term-baricitinib-data-reinforce-potential-in-adolescents-with-aa/2484088/More than half of adolescents treated for alopecia areata (AA) with baricitinib 4mg achieved successful scalp hair response by Week 52, with a response rate reaching 71% among those with baseline Severity of Alopecia Tool (SALT) score of 50-94, according to new data presented at the 2025 Fall Cli
- Study: Nonprescription Balm Performs on Par with Topical Antibiotichttps://practicaldermatology.com/news/study-nonprescription-balm-performs-on-par-with-topical-antibiotic/2474439/A new randomized controlled trial found that a nonprescription repairing balm containing panthenol, madecassoside, and metal salts (CB5) performs equivalently to a topical antibiotic (PSO) for wound healing after cryotherapy of actinic keratoses (AKs).
- SEEN Expands Pediatric Line with Fragrance-Free Baby Shampoo and Body Washhttps://practicaldermatology.com/news/seen-expands-pediatric-line-with-fragrance-free-baby-shampoo-and-body-wash/2474436/SEEN has announced the launch of SEEN Baby 2-in-1 Fragrance Free, a new ultra-gentle shampoo and body wash designed specifically for infants and young children with sensitive or eczema-prone skin, according to a news release from the manufacturer.
- FDA Gives Nod to First Cell-Based Gene Therapy for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fda-gives-nod-to-first-cell-based-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa/2474382/The U.S. Food and Drug Administration (FDA) has approved ZEVASKYN (prademagene zamikeracel, pz-cel), making it the first cell-based gene therapy for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The approval addresses a major unmet clinical nee
- Bimekizumab Trials 'Raise the Bar' for HS, Dr. Vivian Shi Sayshttps://practicaldermatology.com/news/Bimekizumab-Trials-Raise-Bar-HS-Dr-Vivian-Shi-Says/2473933/More than half of hidradenitis suppurativa (HS) patients treated with bimekizumab (BIMZELX, UCB) had no draining tunnels (DTs) at 2 years, and 63.6% reported no or mild skin pain, compared to 10.0% at baseline, according to new data presented at the 2025 American Academy of Dermatology (AAD) Annu
- New Baricitinib AA Data for Adolescents Could Be 'Game-Changing'https://practicaldermatology.com/news/New-Baricitinib-AA-Data-Adolescents-Could-Be-Game-Changing/2471600/Patients ages 12 to under 18 with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes at Week 36 in the Phase 3 BRAVE-AA-PEDS study, presented as a late-breaker at the 202